Thomas R. Kosten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas R. Kosten has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Alison Oliveto
Department of Psychiatry, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, CT, USA
6 shared publicationsAlan Feingold
From the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn., and the VA Connecticut Healthcare System, West Haven, Conn
4 shared publications- James Poling
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
3 shared publications Kishor Gonsai
From the Department of Psychiatry, Yale University School of Medicine and VA Connecticut Healthcare System, West Haven, Conn
3 shared publications- Alison Oliveto
University of Arkansas for Medical Sciences
2 shared publications A Singha
1 shared publication
Latest Publications
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e191-e192
Cognitive and cardiovascular effects of carvedilol in recently abstinent, cocaine-dependent patients
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e191-e192
Cognitive and cardiovascular effects of carvedilol in recently abstinent, cocaine-dependent patients
- 1 October 2005
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 108 (1) , 76-85
Immunotherapy for the treatment of drug abuse
- 1 October 2005
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 108 (1) , 76-85
Immunotherapy for the treatment of drug abuse
- 10 August 2005
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (3) , 644-650
Cue-Induced Brain Activity Changes and Relapse in Cocaine-Dependent Patients
This study used functional magnetic resonance imaging (fMRI) to examine the association between brain activation during exposure to cocaine-related cues and relapse to drug use in cocaine-dependent (CD) patients. We imaged 17 CD subjects during a 2-week in-patient stay. The subjects then entered a 10-week outpatient placebo-controlled, double-blind randomized clinical trial where urine toxicologies were assessed three times weekly to calculate the treatment effectiveness score (TES). Worse TES correlated with BOLD activation in the left precentral, superior temporal, and posterior cingulate cortices (PCC), and right middle temporal and lingual cortices (R>0.65; P<0.005). The left PCC activation also distinguished eight nonrelapsers (TES above mean and completed treatment) from nine relapsers. Cocaine-free urines were significantly greater in the nonrelapsers (92%) than in the relapsers (66%), who also remained in treatment for an average of only 3.2 weeks. Self-reports of craving during fMRI did not differ between nonrelapsers and relapsers and did not correlate with TES. Relapse to cocaine abuse was associated with increased activation in the sensory association cortex, the motor cortex, and PCC while viewing images of cocaine-related cues. These results suggest that relapse to cocaine abuse is associated with increased brain activation to cocaine cues in sensory, motor, and cognitive-emotional processing areas. This physiological activation was a better predictor of relapse than subjective reports of craving, and may be a useful target for treatment development.
- 10 August 2005
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (3) , 644-650
Cue-Induced Brain Activity Changes and Relapse in Cocaine-Dependent Patients
This study used functional magnetic resonance imaging (fMRI) to examine the association between brain activation during exposure to cocaine-related cues and relapse to drug use in cocaine-dependent (CD) patients. We imaged 17 CD subjects during a 2-week in-patient stay. The subjects then entered a 10-week outpatient placebo-controlled, double-blind randomized clinical trial where urine toxicologies were assessed three times weekly to calculate the treatment effectiveness score (TES). Worse TES correlated with BOLD activation in the left precentral, superior temporal, and posterior cingulate cortices (PCC), and right middle temporal and lingual cortices (R>0.65; P<0.005). The left PCC activation also distinguished eight nonrelapsers (TES above mean and completed treatment) from nine relapsers. Cocaine-free urines were significantly greater in the nonrelapsers (92%) than in the relapsers (66%), who also remained in treatment for an average of only 3.2 weeks. Self-reports of craving during fMRI did not differ between nonrelapsers and relapsers and did not correlate with TES. Relapse to cocaine abuse was associated with increased activation in the sensory association cortex, the motor cortex, and PCC while viewing images of cocaine-related cues. These results suggest that relapse to cocaine abuse is associated with increased brain activation to cocaine cues in sensory, motor, and cognitive-emotional processing areas. This physiological activation was a better predictor of relapse than subjective reports of craving, and may be a useful target for treatment development.
- 9 July 2005
- Published by Wiley in The American Journal on Addictions
- Vol. 14 (4) , 307-310
What Are America's Opportunities for Harm Reduction Strategies in Opiate Dependence?
(2005). What Are America's Opportunities for Harm Reduction Strategies in Opiate Dependence? American Journal on Addictions: Vol. 14, No. 4, pp. 307-310.
- 9 July 2005
- Published by Wiley in The American Journal on Addictions
- Vol. 14 (4) , 307-310
What Are America's Opportunities for Harm Reduction Strategies in Opiate Dependence?
(2005). What Are America's Opportunities for Harm Reduction Strategies in Opiate Dependence? American Journal on Addictions: Vol. 14, No. 4, pp. 307-310.
- 2 January 2005
- Published by Wiley in The American Journal on Addictions
- Vol. 14 (1) , 8-17
Desipramine Treatment for Cocaine Dependence in Buprenorphine‐ or Methadone‐treated Patients: Baseline Urine Results as Predictor of Response
The prognostic importance of baseline urines for cocaine was examined in a randomized, placebo‐controlled, twelve‐week clinical trial in 165 opioid‐and cocaine‐dependent patients who were treated with desipramine (DMI) in combination with buprenorphine (BUP) or methadone (Meth). Patients with a cocaine‐positive urine at baseline (CU+) had significantly fewer cocaine‐free urines than those with a negative urine at baseline (CU‐neg). The CU+ patients showed no treatment effects of DMI compared to placebo, but the CU‐neg patients showed a treatment effect of DMI. This DMI effect was significant in patients maintained on BUP but not on Meth.
- 2 January 2005
- Published by Wiley in The American Journal on Addictions
- Vol. 14 (1) , 8-17
Desipramine Treatment for Cocaine Dependence in Buprenorphine‐ or Methadone‐treated Patients: Baseline Urine Results as Predictor of Response
The prognostic importance of baseline urines for cocaine was examined in a randomized, placebo‐controlled, twelve‐week clinical trial in 165 opioid‐and cocaine‐dependent patients who were treated with desipramine (DMI) in combination with buprenorphine (BUP) or methadone (Meth). Patients with a cocaine‐positive urine at baseline (CU+) had significantly fewer cocaine‐free urines than those with a negative urine at baseline (CU‐neg). The CU+ patients showed no treatment effects of DMI compared to placebo, but the CU‐neg patients showed a treatment effect of DMI. This DMI effect was significant in patients maintained on BUP but not on Meth.
- 1 November 2004
- Published by Elsevier in Biological Psychiatry
- Vol. 56 (10) , 771-777
New medication strategies for comorbid substance use and bipolar affective disorders
- 1 November 2004
- Published by Elsevier in Biological Psychiatry
- Vol. 56 (10) , 771-777
New medication strategies for comorbid substance use and bipolar affective disorders
- 6 May 2004
- Published by Wiley in The American Journal on Addictions
- Vol. 13 (S1) , S1-S7
Buprenorphine for Office‐based Practice: Consensus Conference Overview
This overview of the March 2003 conference on the U.S. national buprenorphine implementation program is developed to inform the practitioner about the positive experience that has been accumulated worldwide on the use of buprenorphine for office‐based practice. The first paper delineates the challenges for American psychiatry in moving buprenorphine forward into general practice. Most psychiatrists are unprepared to work with opiate‐dependent patients or to use buprenorphine. The international successes with office‐based buprenorphine from France and Australia are presented in the next papers, followed by presentations on several U.S. studies using buprenorphine in the community for detoxification and office‐based maintenance. These experiences have thus far confirmed buprenorphine's utility and promise for opiate addiction treatment in the U.S. Finally, two national monitoring programs have been implemented to assess the public health impact of this new treatment opportunity. This opportunity has a three‐year window, however, and a critical need will be to attract a sufficient number of physicians into prescribing buprenorphine / naloxone in order to allow our patients increased access to this treatment.
- 6 May 2004
- Published by Wiley in The American Journal on Addictions
- Vol. 13 (S1) , S1-S7
Buprenorphine for Office‐based Practice: Consensus Conference Overview
This overview of the March 2003 conference on the U.S. national buprenorphine implementation program is developed to inform the practitioner about the positive experience that has been accumulated worldwide on the use of buprenorphine for office‐based practice. The first paper delineates the challenges for American psychiatry in moving buprenorphine forward into general practice. Most psychiatrists are unprepared to work with opiate‐dependent patients or to use buprenorphine. The international successes with office‐based buprenorphine from France and Australia are presented in the next papers, followed by presentations on several U.S. studies using buprenorphine in the community for detoxification and office‐based maintenance. These experiences have thus far confirmed buprenorphine's utility and promise for opiate addiction treatment in the U.S. Finally, two national monitoring programs have been implemented to assess the public health impact of this new treatment opportunity. This opportunity has a three‐year window, however, and a critical need will be to attract a sufficient number of physicians into prescribing buprenorphine / naloxone in order to allow our patients increased access to this treatment.
- 4 March 2004
- Published by Wiley in The American Journal on Addictions
- Vol. 13 (2) , 191-201
Depression Predicts Higher Rates of Heroin Use on Desipramine with Buprenorphine than with Methadone
The effect of lifetime depression was examined in a randomized clinical trial in 164 opioid‐ and cocaine‐dependent patients who were treated with desipramine in combination with either methadone or buprenorphine. We examined treatment retention, illicit opioid and cocaine use, and depressive symptoms, and found that opioid‐free urines at baseline, but not later in treatment, were greater among the depressed than non‐depressed patients. Among the depressed patients, depressive symptoms at baseline, but not later in treatment, were greater in patients treated with buprenorphine than methadone. Desipramine did not reduce depressive symptoms more than placebo. Finally, the depressed patients treated with desipramine and buprenorphine showed the least improvement in opioid‐free urines, while the non‐depressed patients treated with desipramine and methadone had more opioid‐free urines than those patients treated with placebo desipramine. Cocaine‐free urines showed no association with depression. This poor outcome with desipramine and buprenorphine suggests that this medication combination is not indicated in depressed opioid‐dependent patients. (Am J Addict 2004;13:191–201)
- 4 March 2004
- Published by Wiley in The American Journal on Addictions
- Vol. 13 (2) , 191-201
Depression Predicts Higher Rates of Heroin Use on Desipramine with Buprenorphine than with Methadone
The effect of lifetime depression was examined in a randomized clinical trial in 164 opioid‐ and cocaine‐dependent patients who were treated with desipramine in combination with either methadone or buprenorphine. We examined treatment retention, illicit opioid and cocaine use, and depressive symptoms, and found that opioid‐free urines at baseline, but not later in treatment, were greater among the depressed than non‐depressed patients. Among the depressed patients, depressive symptoms at baseline, but not later in treatment, were greater in patients treated with buprenorphine than methadone. Desipramine did not reduce depressive symptoms more than placebo. Finally, the depressed patients treated with desipramine and buprenorphine showed the least improvement in opioid‐free urines, while the non‐depressed patients treated with desipramine and methadone had more opioid‐free urines than those patients treated with placebo desipramine. Cocaine‐free urines showed no association with depression. This poor outcome with desipramine and buprenorphine suggests that this medication combination is not indicated in depressed opioid‐dependent patients. (Am J Addict 2004;13:191–201)
- 1 June 2003
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 70 (3) , 315-325
Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients
- 1 June 2003
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 70 (3) , 315-325
Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients
Effects of reducing contingency management values on heroin and cocaine use for buprenorphine‐ and desipramine‐treated patients
Aims During 3 months where contingency management (CM) had an escalating value for each consecutive drug‐free urine (escalating CM), cocaine‐ and heroin‐abusing patients significantly increased drug‐free urines. The ‘escalating CM’ was eliminated during months 4–6 to assess any reduction in drug‐free urines. Design Patients who completed a 3‐month, randomized, double‐blind, trial evaluating CM versus non‐CM and desipramine (DMI) versus placebo, had an ‘escalating CM’ eliminated during months 4–6. The CM and non‐CM groups were compared using thrice‐weekly urine samples. Setting Out‐patient buprenorphine maintenance for 6 months. Participants All 75 of the 160 original study patients who completed month 3 of the clinical trial. Intervention The ‘escalating CM’ was eliminated for all 3 months and during months 5 and 6 the response requirement was also increased to two and then three consecutive drug‐free urines in order to obtain a voucher. Measurements Urine toxicology for opiates and cocaine. Findings After eliminating the ‘escalating CM’, the CM group showed a decline in combined opioid‐ and cocaine‐free urines. This decline within the CM group was greater in those treated with DMI than placebo. Conclusions Buprenorphine with DMI maintained drug abstinence after eliminating the ‘escalating CM’, but not after increasing the response requirement, suggesting the need for more intensive psychosocial interventions during CM.
Effects of reducing contingency management values on heroin and cocaine use for buprenorphine‐ and desipramine‐treated patients
Aims During 3 months where contingency management (CM) had an escalating value for each consecutive drug‐free urine (escalating CM), cocaine‐ and heroin‐abusing patients significantly increased drug‐free urines. The ‘escalating CM’ was eliminated during months 4–6 to assess any reduction in drug‐free urines. Design Patients who completed a 3‐month, randomized, double‐blind, trial evaluating CM versus non‐CM and desipramine (DMI) versus placebo, had an ‘escalating CM’ eliminated during months 4–6. The CM and non‐CM groups were compared using thrice‐weekly urine samples. Setting Out‐patient buprenorphine maintenance for 6 months. Participants All 75 of the 160 original study patients who completed month 3 of the clinical trial. Intervention The ‘escalating CM’ was eliminated for all 3 months and during months 5 and 6 the response requirement was also increased to two and then three consecutive drug‐free urines in order to obtain a voucher. Measurements Urine toxicology for opiates and cocaine. Findings After eliminating the ‘escalating CM’, the CM group showed a decline in combined opioid‐ and cocaine‐free urines. This decline within the CM group was greater in those treated with DMI than placebo. Conclusions Buprenorphine with DMI maintained drug abstinence after eliminating the ‘escalating CM’, but not after increasing the response requirement, suggesting the need for more intensive psychosocial interventions during CM.